Cefonus-S 500mg/250mg Injection
Marketer
Cronus Biotech Ltd
Salt Composition
Ceftriaxone (500mg) + Sulbactam (250mg)
Overview Cefonus-S 500mg/250mg Injection
Combiflox-500 injection, a dual-action antibiotic, combats diverse bacterial infections by inhibiting microbial proliferation. Administered solely under medical guidance, consistent adherence to the prescribed dosage is crucial; premature cessation may compromise efficacy. Potential side effects, including nausea, vomiting, diarrhea, and dyspepsia, warrant immediate medical consultation if they worsen. Allergic reactions (skin rashes, itching, swelling, respiratory distress) necessitate immediate emergency care. Prior to commencing treatment, disclose all current medications, including those for pre-existing conditions, to your physician. Pregnant or lactating individuals should seek medical advice. Alcohol consumption should be avoided due to the risk of increased drowsiness. While generally non-impairing to driving ability, refrain from operating vehicles if experiencing somnolence or dizziness. Optimal recovery necessitates adequate rest, a nutritious diet, and sufficient hydration. Your doctor might order tests to monitor the medication's impact.
Uses of Cefonus-S 500mg/250mg Injection
Infections caused by bacteria
Major Benefits of Cefonus-S 500mg/250mg Injection:
This medication will be administered by your physician or their designated nurse. Self-medication is strongly discouraged.
Common Side effects of Cefonus-S 500mg/250mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Cefonus-S 500mg/250mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Cefonus-S 500mg/250mg Injection works:
Ceftriaxone and Sulbactam, combined as Cefonus-S 500mg/250mg Injection, offer a dual-action approach to bacterial infection. Ceftriaxone, a crucial antibiotic, disrupts bacterial cell wall synthesis, hindering their ability to thrive. The addition of Sulbactam, a beta-lactamase inhibitor, counters bacterial resistance mechanisms, thereby bolstering Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from using Cefonus-S 500mg/250mg Injection concurrently with alcohol consumption.
PregnancySAFE IF PRESCRIBED
The injectable medication Cefonus-S (500mg/250mg) is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or absent harm to the fetus; nevertheless, clinical data from human trials are scarce.
Breast feedingCAUTION
The administration of Cefonus-S 500mg/250mg Injection to breastfeeding mothers requires careful consideration. It's advised to discontinue breastfeeding for the duration of maternal treatment and until the medication is fully cleared from the mother's system.
DrivingUNSAFE
The administration of Cefonus-S 500mg/250mg Injection can lead to reduced alertness, visual impairment, drowsiness, and dizziness. Driving should be avoided if any of these effects are experienced.
KidneyCONSULT YOUR DOCTOR
Data regarding Cefonus-S 500mg/250mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
The injectable formulation of Cefonus-S (500mg/250mg) requires careful administration in individuals with significant hepatic impairment. A modified dosage regimen for Cefonus-S (500mg/250mg) injection may be necessary. Physician consultation is advised. Altering the dose of Cefonus-S (500mg/250mg) injection is not suggested for patients exhibiting mild or moderate liver dysfunction.
What if you forget to take Cefonus-S 500mg/250mg Injection :
Omit a Cefonus-S 500mg/250mg Injection dose? Seek medical advice immediately.
Facts to Know About Cefonus-S 500mg/250mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
3,018 People bought this recently